+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Nintedanib"

Nintedanib Esylate Market - Global Forecast 2026-2032 - Product Thumbnail Image

Nintedanib Esylate Market - Global Forecast 2026-2032

  • Report
  • September 2026
  • 188 Pages
  • Global
From
Nintedanib Generics Market - Global Forecast 2026-2032 - Product Thumbnail Image

Nintedanib Generics Market - Global Forecast 2026-2032

  • Report
  • September 2026
  • 185 Pages
  • Global
From
From
Sarcoidosis Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Sarcoidosis Therapeutics - Global Strategic Business Report

  • Report
  • September 2026
  • 175 Pages
  • Global
From
Lung Disease Therapeutics Market - Global Strategic Business Report - Product Thumbnail Image

Lung Disease Therapeutics Market - Global Strategic Business Report

  • Report
  • September 2026
  • 389 Pages
  • Global
From
Pulmonary Fibrosis Treatment - Global Strategic Business Report - Product Thumbnail Image

Pulmonary Fibrosis Treatment - Global Strategic Business Report

  • Report
  • September 2026
  • 376 Pages
  • Global
From
From
Interstitial Lung Disease Market Report 2026 - Product Thumbnail Image

Interstitial Lung Disease Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Idiopathic Pulmonary Fibrosis Market Report 2026 - Product Thumbnail Image

Idiopathic Pulmonary Fibrosis Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Idiopathic Pulmonary Fibrosis - Global Strategic Business Report - Product Thumbnail Image

Idiopathic Pulmonary Fibrosis - Global Strategic Business Report

  • Report
  • September 2026
  • 202 Pages
  • Global
From
From
OFEV Sales Forecast and Market Size Analysis - 2034 - Product Thumbnail Image

OFEV Sales Forecast and Market Size Analysis - 2034

  • Report
  • April 2026
  • 30 Pages
  • Global
From
From
From
From
From
From
From
Loading Indicator

Nintedanib is a drug used to treat respiratory diseases such as idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-associated interstitial lung disease (SSc-ILD). It is a tyrosine kinase inhibitor that works by blocking the activity of certain proteins that are involved in the development of fibrosis. Nintedanib is approved by the US Food and Drug Administration (FDA) for the treatment of IPF and SSc-ILD. It is also approved in Europe and other countries for the treatment of IPF. Nintedanib is marketed by Boehringer Ingelheim, a German pharmaceutical company. Other companies involved in the market include Novartis, AstraZeneca, and GlaxoSmithKline. Show Less Read more